|
Global Chronic Lymphocytic Leukemia (CLL) Markets 2019-2026: With Rituxan Soon Facing Biosimilar Competition, Gazyva and Imbruvica are Set to Become Market Leaders Within CLL
Tuesday, July 16, 2019
DUBLIN, July 16, 2019 /PRNewswire/ -- The "Chronic Lymphocytic Leukemia (CLL)" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Chronic lymphocytic leukemia (CLL) is a disease characterized by an accumulation of mature malignant B lymphocytes in the peripheral blood, bone marrow, and lymph nodes. Diagnosis of CLL is defined by an absolute B lymphocyte count of at least 5,000 cells per microliter for three months. CLL represents the most common form of leukemia in Western countries, and predominantly affects older individuals; in the US, the median age at diagnosis is 72 years.
Recent events and opinion
-- The size of the CLL market is expected to nearly double by 2026,
reaching $8.0bn in the US, Japan, and five major EU markets.
-- Imbruvica is the preferred treatment option for relapsed/refractory
patients.
-- Incident cases will increase substantially over the forecast period,
with a growth rate of around 40%.
-- With Rituxan soon facing biosimilar competition, Gazyva and Imbruvica
are set to become market leaders within CLL.
-- Pipeline drugs for CLL will focus on relapsed/refractory and high-risk
populations, which are areas of high unmet need.
Key Topics Covered:
FORECAST: CHRONIC LYMPHOCYTIC LEUKEMIA (Published on 31 January 2019)
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Arzerra
Product Profile (Late Stage): Calquence
Product Profile: Copiktra
Product Profile: Gazyva
Product Profile: Imbruvica
Product Profile (Late Stage): Kymriah
Product Profile: Rituxan
Product Profile: Treanda/Bendeka
Product Profile: Venclexta
Product Profile: Zydelig
Product Profile (Late Stage): Ublituximab
Product Profile (Late Stage): Zanubrutinib
TREATMENT: CHRONIC LYMPHOCYTIC LEUKEMIA (Published on 03 February 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Cll
EPIDEMIOLOGY: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (Published on 07 June 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: CHRONIC LYMPHOCYTIC LEUKEMIA (Published on 31 January 2019)
Overview
Product Overview
Product Profile: Arzerra
Product Profile: Copiktra
Product Profile: Gazyva
Product Profile: Imbruvica
Product Profile: Rituxan
Product Profile: Treanda/Bendeka
Product Profile: Venclexta
Product Profile: Zydelig
PIPELINE: CHRONIC LYMPHOCYTIC LEUKEMIA (Published on 31 January 2019)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Calquence
Product Profile (Late Stage): Kymriah
Product Profile (Late Stage): Ublituximab
Product Profile (Late Stage): Zanubrutinib
For more information about this report visit https://www.researchandmarkets.com/r/31pkpi
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-chronic-lymphocytic-leukemia-cll-markets-2019-2026-with-rituxan-soon-facing-biosimilar-competition-gazyva-and-imbruvica-are-set-to-become-market-leaders-within-cll-300885698.html
SOURCE Research and Markets
|
|
|
|
|
|
 |
Cheetah Mobile Inc. Files Its Annual Report on Form 20-F | Apr 25, 2024
|
|
AI Is Here to Stay: Marketing Must Adopt or Get Left Behind: New Research From Info-Tech Research Group | Apr 25, 2024
|
|
DesignRush Announces the Top-Rated SEO Companies in April 2024 | Apr 25, 2024
|
|
Leading Des Moines Digital Agency Webspec Acquires Local Drupal Development Firm | Apr 25, 2024
|
|
Click360 Marketing Unveils Innovative B2B SEO Marketing Plan to Transform Digital Presence for Businesses | Apr 25, 2024
|
|
ClickReady Marketing Announces Complimentary Website Audit Service for Businesses Looking to Boost Their Online Presence | Apr 25, 2024
|
|
Wix Studio Expands Growth Opportunity for Partners to Sell Website Templates and Monetize their Creations | Apr 25, 2024
|
|
Chris DeSaye, CTO of José Andrés Group, and Erick Williams, James Beard Award-Winning Chef, Join OpenTable's Advisory Board | Apr 25, 2024
|
|
Worker Earnings Down for Q1 Amid Inflation Woes, According to Ludwig Institute | Apr 25, 2024
|
|
Keeper Security Empowers Users with Integrated Passphrase Generator | Apr 25, 2024
|
|
|
|
